p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents - PubMed

p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents

K Wehrly et al. Methods. 1997 Aug.

Abstract

Antigen capture enzyme-linked immunosorbent assay (ELISA) for quantitation of the p24 gag protein of human immunodeficiency virus type-1 (HIV-1) is currently the most common method used to demonstrate virus replication both in vivo and in vitro. The present paper describes an ELISA employing readily available inexpensive reagents and gives detailed suggestions for optimizing the variables for specific purposes. The assay is as sensitive as commercial kits (25 pg/ml) and has a linear dose response over a wide range of p24 concentrations (25-1000 pg/ml). For these reasons, as well as its low cost, this assay has proven useful in a variety of research applications. This assay also has been found to be effective in detecting the gag protein of human immunodeficiency virus type-2 and simian immunodeficiency virus.

Similar articles

• A serological screening assay of human immunodeficiency virus type 1 antibodies based on recombinant protein p24-gp41 as a fusion protein expressed in Escherichia coli.

  Mahboudi F, Irina NA, Chevalier A, Ghadiri A, Adeli A, Amini-Bavil-Olyaee S, Barkhordari F, Farzamfar B, Alinejad M. Mahboudi F, et al. J Biotechnol. 2006 Sep 1;125(2):295-303. doi: 10.1016/j.jbiotec.2006.03.021. Epub 2006 May 2. J Biotechnol. 2006. PMID: 16647775

• [Study of antigenic structure of HIV-1 protein p24 using monoclonal antibodies].

  Konovalov EE, Loktev VB, Pokrovskiĭ AG, Fediuk NV, Chernykh AI, Nechaev IuS, Kuliandin SA, Kipriianov SM, Ofitserov VI. Konovalov EE, et al. Vestn Ross Akad Med Nauk. 1992;(9-10):55-9. Vestn Ross Akad Med Nauk. 1992. PMID: 1283723 Review. Russian.

Cited by

• High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive Macaques.

  Kannanganat S, Wyatt LS, Gangadhara S, Chamcha V, Chea LS, Kozlowski PA, LaBranche CC, Chennareddi L, Lawson B, Reddy PB, Styles TM, Vanderford TH, Montefiori DC, Moss B, Robinson HL, Amara RR. Kannanganat S, et al. J Immunol. 2016 Nov 1;197(9):3586-3596. doi: 10.4049/jimmunol.1600629. Epub 2016 Sep 28. J Immunol. 2016. PMID: 27683750 Free PMC article.

• CRISPR-Cas9 genome engineering of primary CD4⁺ T cells for the interrogation of HIV-host factor interactions.

  Hultquist JF, Hiatt J, Schumann K, McGregor MJ, Roth TL, Haas P, Doudna JA, Marson A, Krogan NJ. Hultquist JF, et al. Nat Protoc. 2019 Jan;14(1):1-27. doi: 10.1038/s41596-018-0069-7. Nat Protoc. 2019. PMID: 30559373 Free PMC article.

• Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication.

  Forshey BM, von Schwedler U, Sundquist WI, Aiken C. Forshey BM, et al. J Virol. 2002 Jun;76(11):5667-77. doi: 10.1128/jvi.76.11.5667-5677.2002. J Virol. 2002. PMID: 11991995 Free PMC article.

• Polymorphisms in Human APOBEC3H Differentially Regulate Ubiquitination and Antiviral Activity.

  Chesarino NM, Emerman M. Chesarino NM, et al. Viruses. 2020 Mar 30;12(4):378. doi: 10.3390/v12040378. Viruses. 2020. PMID: 32235597 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database